Advanced search
Publication Cover
Hepatic Oncology Volume 5, 2018 - Issue 1
Submit an article Journal homepage
5,979
Views
32
CrossRef citations to date
0
Altmetric
Review

Molecular classification of hepatocellular adenomas: impact on clinical practice

Anne-Laure Védie1 Service d’Hépatologie, Hôpital Jean Verdier,Hôpitaux universitaires Paris-Seine-Saint-Denis, Assistance publique Hôpitaux de Paris, Bondy, France;2 Unité mixte de Recherche 1162, Génomique fonctionnelle des Tumeurs solides,Institut National de la Santé et de la Recherche médicale, Paris, France
,
Olivier Sutter3 Service de Radiologie, Hôpital Jean Verdier,Hôpitaux universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France
,
Marianne Ziol4 Service d’Anatomopathologie, Hôpital Jean Verdier,Hôpitaux universitaires Paris-Seine-Saint-Denis, Assistance-publique Hôpitaux de Paris, Bondy, France;5 Unité de Formation et de Recherche Santé Médecine et Biologie humaine,Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Paris, France
&
Jean-Charles Nault1 Service d’Hépatologie, Hôpital Jean Verdier,Hôpitaux universitaires Paris-Seine-Saint-Denis, Assistance publique Hôpitaux de Paris, Bondy, France;2 Unité mixte de Recherche 1162, Génomique fonctionnelle des Tumeurs solides,Institut National de la Santé et de la Recherche médicale, Paris, France;5 Unité de Formation et de Recherche Santé Médecine et Biologie humaine,Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Paris, FranceCorrespondence[email protected]
Article: HEP04 | Received 29 Sep 2017, Accepted 20 Feb 2018, Published online: 09 Apr 2018

References

  • Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N. Engl. J. Med. 294, 470–472 (1976).
  • Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors from molecular classification to personalized clinical care. Gastroenterology 144, 888–902 (2013).
  • Rooks JB, Ory HW, Ishak KG et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242, 644–648 (1979).
  • Belghiti J, Cauchy F, Paradis V, Vilgrain V. Diagnosis and management of solid benign liver lesions. Nat. Rev. Gastroenterol. Hepatol. 11, 737–749 (2014).
  • Cherqui D, Rahmouni A, Charlotte F et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 22, 1674–1681 (1995).
  • European Association for the Study of the Liver. EASL clinical practice guidelines on the management of benign liver tumours. J. Hepatol. 65, 386–398 (2016).
  • Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Tyler CW Jr. The association between oral contraception and hepatocellular adenoma – a preliminary report. Int. J. Gynaecol. Obstet. 15, 143–144 (1977).
  • Torbenson M, Lee JH, Choti M et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod. Pathol. 15, 189–196 (2002).
  • Svrcek M, Jeannot E, Arrive L et al. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur. J. Endocrinol. 156, 617–621 (2007).
  • Buhler H, Pirovino M, Akobiantz A et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 82, 775–782 (1982).
  • Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J. Pediatr. Gastroenterol. Nutr. 24, 276–279 (1997).
  • Sempoux C, Paradis V, Komuta M et al. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd–Chiari syndrome and other rare hepatic vascular disorders. J. Hepatol. 63, 1173–1180 (2015).
  • Flejou JF, Barge J, Menu Y et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 89, 1132–1138 (1985).
  • Chiche L, Dao T, Salame E et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann. Surg. 231, 74–81 (2000).
  • Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann. Intern. Med. 110, 489–490 (1989).
  • Bieze M, Phoa SS, Verheij J, van Lienden KP, van Gulik TM. Risk factors for bleeding in hepatocellular adenoma. Br. J. Surg. 101, 847–855 (2014).
  • Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 60, 85–89 (2011).
  • van Aalten SM, de Man RA, JN IJ, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br. J. Surg. 99, 911–916 (2012).
  • Kakar S, Grenert JP, Paradis V, Pote N, Jakate S, Ferrell LD. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor. Mod. Pathol. 27, 1499–1509 (2014).
  • Zucman-Rossi J, Jeannot E, Nhieu JT et al. Genotype–phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43, 515–524 (2006).
  • Nault JC, Couchy G, Balabaud C et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 152, 886e880–886e894 (2017).
  • Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J. Hepatol. 67, 1074–1083 (2017).
  • Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int. J. Hepatol. 2013, 315947 (2013).
  • Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 32, 312–315 (2002).
  • Pelletier L, Rebouissou S, Paris A et al. Loss of hepatocyte nuclear factor 1 alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 51, 557–566 (2010).
  • Rebouissou S, Imbeaud S, Balabaud C et al. HNF1 alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J. Biol. Chem. 282, 14437–14446 (2007).
  • Yamagata K, Oda N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455–458 (1996).
  • Bacq Y, Jacquemin E, Balabaud C et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 125, 1470–1475 (2003).
  • Reznik Y, Dao T, Coutant R et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J. Clin. Endocrinol. Metab. 89, 1476–1480 (2004).
  • Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46, 740–748 (2007).
  • Bioulac-Sage P, Laumonier H, Couchy G et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50, 481–489 (2009).
  • Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48, 808–818 (2008).
  • Ronot M, Bahrami S, Calderaro J et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 53, 1182–1191 (2011).
  • van Aalten SM, Thomeer MG, Terkivatan T et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology 261, 172–181 (2011).
  • Pilati C, Amessou M, Bihl MP et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359–1366 (2011).
  • Pilati C, Letouze E, Nault JC et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 25, 428–441 (2014).
  • Nault JC, Fabre M, Couchy G et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol. 56, 184–191 (2012).
  • Paradis V, Champault A, Ronot M et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 46, 140–146 (2007).
  • Paradis V, Benzekri A, Dargere D et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 126, 1323–1329 (2004).
  • Joseph NM, Ferrell LD, Jain D et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod. Pathol. 27, 62–72 (2014).
  • Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 45, 1298–1305 (2007).
  • Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 149, 1192–1205 (2012).
  • Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 36, 927–935 (2002).
  • Hale G, Liu X, Hu J et al. Correlation of exon 3 beta-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Mod. Pathol. 29, 1370–1380 (2016).
  • Rebouissou S, Franconi A, Calderaro J et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology 64, 2047–2061 (2016).
  • Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum. Pathol. 44, 750–758 (2013).
  • Nault JC, Mallet M, Pilati C et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).
  • Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19, 1410–1422 (2013).
  • Calderaro J, Labrune P, Morcrette G et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J. Hepatol. 58, 350–357 (2013).
  • Dokmak S, Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? Liver Int. 35, 2228–2232 (2015).
  • Dokmak S, Paradis V, Vilgrain V et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137, 1698–1705 (2009).
  • Sa Cunha A, Blanc JF, Lazaro E et al. Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management. Gut 56, 307–309 (2007).
  • Roux M, Pigneur F, Calderaro J et al. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI. J. Magn. Reson. Imaging 42, 1249–1258 (2015).
  • Bioulac-Sage P, Cubel G, Taouji S et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am. J. Surg. Pathol. 36, 1691–1699 (2012).
  • Fonseca S, Hoton D, Dardenne S et al. Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. Int. J. Hepatol. 2013, 398308 (2013).
  • van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J. Hepatol. 55, 120–125 (2011).
  • Pan J, Chen L, Fan J et al. Retrospective study of hepatocellular adenomas based on the phenotypic classification system: a report from China. Histol. Histopathol. 29, 243–249 (2014).
  • Bellamy CO, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre. Histopathology 62, 431–445 (2013).
  • Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. Characterization of hepatocellular adenoma based on the phenotypic classification: the Kanazawa experience. Hepatol. Res. 41, 982–988 (2011).
  • Laurent A, Dokmak S, Nault JC et al. European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group. HPB (Oxford) 18, 748–755 (2016).
  • van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 32, 28–37 (2012).
  • de’Angelis N, Memeo R, Calderaro J et al. Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit. HPB (Oxford) 16, 783–788 (2014).
  • van Vledder MG, van Aalten SM, Terkivatan T, de Man RA, Leertouwer T, Ijzermans JN. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J. Vasc. Interv. Radiol. 22, 787–793 (2011).
  • van der Sluis FJ, Bosch JL, Terkivatan T, de Man RA, Ijzermans JN, Hunink MG. Hepatocellular adenoma: cost–effectiveness of different treatment strategies. Radiology 252, 737–746 (2009).
  • Klompenhouwer AJ, Broker MEE, Thomeer MGJ, Gaspersz MP, de Man RA, IJzermans JNM. Retrospective study on timing of resection of hepatocellular adenoma. Br. J. Surg. 104, 1695–1703 (2017).
  • Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 51, 855–856 (2007).
  • Chiche L, David A, Adam R et al. Liver transplantation for adenomatosis: European experience. Liver Transpl. 22, 516–526 (2016).
  • Poussin K, Pilati C, Couchy G et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology 2, e27090 (2013).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.